论文部分内容阅读
目的:分析肺癌中间变性淋巴瘤激酶(ALK)蛋白与棘皮动物微管结合蛋白4(EML4)-ALK基因的表达及意义。方法:选择2015年7月至2016年7月重庆市长寿区人民医院收治的非小细胞肺癌患者73例,给予ALK蛋白检测,并以ALK蛋白阳性表达及阴性表达患者为研究对象,检测其EML4-ALK基因阳性表达情况,同时,分析ALK蛋白阳性、EML4-ALK基因阳性与病理学指标的关系。结果:经检测可知,ALK蛋白表达阳性率16.4%;EML4-ALK基因阳性率33.3%。A组ALK蛋白阳性患者年龄>60岁、男性患者、吸烟者、临床分期Ⅰ+Ⅱ期、肺腺癌占比低于B组,且A组EML4-ALK基因阳性患者>60岁、吸烟者、非腺癌、有EGFR突变占比低于B1组,差异具有统计学意义(P<0.05)。结论:肺癌中,ALK蛋白阳性表达与EML4-ALK基因阳性表达的一致性较好。
Objective: To analyze the expression of ALK protein and echinoderm microtubule binding protein 4 (EML4) -ALK gene in lung cancer and its significance. Methods: From July 2015 to July 2016, 73 patients with non-small cell lung cancer admitted to Changshou District People’s Hospital of Chongqing were enrolled in this study. ALK protein was detected and ALK protein positive and negative expression were detected in patients with EML4 -ALK gene positive expression, at the same time, analysis of ALK protein positive, EML4-ALK gene positive and pathological indicators. Results: The results showed that the positive rate of ALK protein was 16.4% and the positive rate of EML4-ALK gene was 33.3%. The ALK protein positive patients in group A were more than 60 years old, the proportion of male patients, smokers, clinical stage Ⅰ + Ⅱ, lung adenocarcinoma was lower than that of group B, and those with positive EML4-ALK gene in group A were more than 60 years old. Non-adenocarcinoma, EGFR mutation accounted for less than B1 group, the difference was statistically significant (P <0.05). Conclusions: The consistency of positive expression of ALK protein and positive expression of EML4-ALK gene in lung cancer is better.